Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC
Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.
Read More
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
Listen
Improving Identification Within Asian American Subgroups With Ovarian Cancer
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
FDA Grants Fast Track Designation to LYT-200 in Head and Neck Cancers
The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.
The Allina Health Approach to Genomic Testing for Cancer
In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.
